← Back to Clinical Trials
Recruiting Phase 2 NCT05842382

Effect of High Dose Intravenous Vitamin C in Severe Pneumonia

Trial Parameters

Condition Pneumonia
Sponsor Clinical Research Centre, Malaysia
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 484
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-01-12
Completion 2025-12
Interventions
Active IngredientPlacebo

Brief Summary

This trial is a multicenter, randomized, double-blind, two-arm, parallel-group, placebo-controlled trial to investigate the effect of high dose intravenous (IV) Vitamin C as an adjunct to the standard of care for patients with severe pneumonia versus placebo in ICU.

Eligibility Criteria

Inclusion Criteria: * Patients who are aged 18 and above * Patients who are diagnosed with severe pneumonia * Patients who are mechanically ventilated Exclusion Criteria: * Known allergy to Vitamin C * Pregnancy * Known history of ongoing concomitant infection * Participation in another clinical trial and/or receipt of investigational drugs within 4 weeks prior to enrollment * Moribund patient with multiorgan failure to the judgement of the treating physician, who is not expected to survive 24 hours * Patient who requires home oxygen therapy or mechanical ventilation, including tracheostomy or non-invasive ventilation, except for CPAP/BIPAP for sleep-disordered breathing * Known history of previous or current diagnosis of renal stones * Known diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency * Known diagnosis of hemochromatosis * Known diagnosis of poorly controlled chronic pulmonary disease, including: * Chronic obstructive pulmonary disease with oxygen therapy * Chroni

Related Trials